Company
Company

Technology powers us. Drug development defines us.

Technology powers us. Drug development defines us.

Novorex is a drug development company integrating AI, FBDD, and biophysical validation to identify real binders and advance high-unmet-need CNS and inflammation pipelines.

Novorex is a drug development company integrating AI, FBDD, and biophysical validation to identify real binders and advance high-unmet-need CNS and inflammation pipelines.

02 / Key Leadership
Leadership driving real-binder discovery

The leadership team combines structure-based discovery, translational biophysics, development execution, and corporate finance to support Novorex's global growth.

02 / 05
Founder & CEO

WooSung Son

Structure-based novel compound discovery and prediction leadership with global R&D execution experience.
Global Experience Snapshot

Global structure-based drug discovery leader with US and Korea R&D experience.

Key Global Achievements
  • GPCR and membrane-protein POC research and UCSD Opella Group collaboration experience.
  • Secured global-level structure-based drug design and large-target analysis capabilities.
  • Applied AI-based drug discovery platforms to real projects, generating globally competitive candidates.
Global Network & Execution
  • Collaborative research through US academic and global research networks.
  • Led CRO/CDMO partnership strategy development and execution.
B.S. Pharmacy, Seoul National University / M.S.-Ph.D. Physical Pharmacy, Seoul National University
Chief Development Officer & VP

HyeLin Park

Innovative drug R&D and commercialization execution from discovery to IND-enabling stages.
Global Experience Snapshot

End-to-end global development leader from discovery to IND-enabling execution.

Key Global Achievements
  • Led IND package development from preclinical stage in collaboration with global pharma and CROs.
  • Established global-standard development strategies integrating PK/PD, safety, and CMC.
  • Externally validated development expertise through regulatory and translational project execution.
Global Network & Execution
  • Led cross-functional communication and project management with global CROs.
  • Executed development strategy aligned with global regulatory standards.
B.S. Biology, Kyonggi University
Chief Science Officer

JongSoo Lim

Biophysics-based target validation and translational science leadership for real-binder evidence.
Global Experience Snapshot

Global translational science expert bridging biophysics and clinical relevance.

Key Global Achievements
  • Global-level POC validation via biophysical methods across multiple targets.
  • Drug discovery strategy development and execution in diverse global programs.
  • Award-winning research in magnetic resonance and translational validation science.
Global Network & Execution
  • Target validation and MoA analysis based on global academic networks.
  • Early efficacy and MoA validation experience with overseas CROs.
B.S. Pharmacy, Seoul National University / M.S. Physical Pharmacy, Seoul National University / Ph.D. Translational validation science
Chief Financial Officer

HanHo Choi

Finance, accounting, IPO-readiness, valuation, assurance, and corporate governance support.
Professional Background
  • Manager, PwC Samil Accounting.
  • Dual-Licensed CPA (Korea & US).
Core Expertise
  • Broad assurance service including Financial Due Diligence, IFRS conversion, valuation, and internal control implementation.
  • Directed multiple designated audits for companies preparing for initial public offerings.
Corporate Execution
  • Supports finance governance, capital-market readiness, and partner-facing financial communication.
B.S. Business Administration, Sungkyunkwan University